Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO - (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI - (bempedoic acid and ezetimibe) tablet approved in Switzerland
(bempedoic acid)
is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients -
- Bempedoic acid and its fixed combination drug product with ezetimibe both deliver significant reductions in LDL-C when added to a statin or other lipid-lowering therapies
1,2
- Two-thirds of patients in Switzerland with very high cardiovascular risk do not achieve LDL-C target values set out by the European Society of Cardiology,